Bigfoot Looks To Unlock More Effective Treatments For Type II Diabetics
Bigfoot Biomedical’s Unity system pairs continuous glucose monitoring with smart insulin pen caps, giving patients recommendations on insulin dosing. Because patient interaction is involved, Bigfoot Biomedical can deliver insulin pump-like results to pump-ineligible type II diabetics.
You may also be interested in...
In this final Exec Chat in our series with leaders of major diabetes companies that presented at ADA’s Scientific Session 2023, Bigfoot Biomedical’s CMO James Malone and senior medical director Jeanne Jacoby discuss plans for the firm’s Unity diabetes management platform and its shift into the pharmacy channel.
Insulet will acquire insulin pump patents from Bigfoot Biomedical for $25m, which Bigfoot will use to expand its Unity diabetes management system. Insulet also announced the acquisition of automated insulin delivery assets held by Automated Glucose Control.
Ohad Cohen, director of medical affairs for Medtronic Diabetes EMEA, talked to Medtech Insight about the published results from the ADAPT trial, which showed that Medtronic’s advanced hybrid closed loop insulin delivery technology provides better glycemic control than standard therapies.